Urolithin A vs Ca-AKG for Dog Longevity: A Research Comparison

What this article covers

These are the two most-cited compounds in the canine longevity-supplement conversation: urolithin A (which activates mitophagy) and calcium alpha-ketoglutarate (which feeds Krebs-cycle metabolism). They target different cellular mechanisms, have different research bases, and combine well. This article lays out what each one is, what the published research actually shows, and how to think about them for adult and senior dogs.

A note on framing: this is informational content using structure/function language. We do not claim either compound addresses any specific disease. Vector Canis is a dietary supplement, not a veterinary pharmaceutical. Talk to your veterinarian before starting any supplement, especially if your dog is on prescription veterinary pharmaceuticals.

Why mitochondria matter in aging dogs

Mitochondria are the small organelles inside almost every cell that convert nutrients into ATP. Across mammals, mitochondrial decline is a consistent feature of aging — accumulating damage, reduced biogenesis, slower quality control. A 2024 Sports Medicine review framed mitochondria specifically as nutritional targets to maintain muscle health and physical function during aging ¹. The caloric-restriction-mimetic class of compounds (which includes both urolithin A and AKG) is reviewed in ².

In aging dogs, the visible signs are familiar: slower stair-climbing, shorter walks, longer recovery, reduced muscle mass on the topline. The mitochondrial-quality-control machinery is one of the underlying mechanisms; supporting it is the Vector Canis premise.

Urolithin A — mitophagy

What it is. A gut-microbial metabolite produced when ellagitannins (in pomegranates, walnuts, some berries) reach the gut microbiome. Direct supplementation bypasses the microbiome-conversion variability.

Mechanism. Activates mitophagy — the selective autophagy of damaged mitochondria. The pivotal 2016 Nature Medicine paper demonstrated mitophagy induction and lifespan prolongation in C. elegans alongside increased muscle function in rodents ³. The 2021 review covers the broader urolithin A health-and-aging story ⁴.

Animal evidence. The 2016 Ryu paper is the foundational rodent-and-worm work ³. Subsequent reviews build on it ⁴⁵.

Human evidence (translational reference). Andreux et al. 2019 in Nature Metabolism — randomized, double-blind, placebo-controlled safety and biomarker study in older adults ⁶. Liu et al. 2022 in JAMA Network Open — four-month RCT in older adults; muscle endurance and mitochondrial-health biomarker improvements ⁷. Singh et al. 2022 in Cell Reports Medicine — four-month RCT at 500 mg/day in middle-aged adults; muscle strength and exercise performance improvements ⁸. A 2024 systematic review synthesizes the body of work ⁵.

Canine evidence. Dedicated canine RCTs at Vector Canis doses do not yet exist in the public literature. We body-weight-scale from the human-trial dose range and apply veterinary-formulation safety review.

Dose. Most-studied human dose is 500 mg once daily. Vector Canis doses urolithin A body-weight-scaled for adult-to-senior medium-large breeds.

Calcium alpha-ketoglutarate (Ca-AKG) — Krebs cycle

What it is. The calcium salt of alpha-ketoglutarate, a Krebs-cycle intermediate. AKG is endogenous — cells produce and consume it constantly. Supplementation studies the effect of dietary AKG on circulating and tissue levels.

Mechanism. AKG sits at a metabolic hub: it intersects with amino-acid metabolism and is a substrate for a class of dioxygenase enzymes that regulate DNA and histone methylation. A 2014 Nature paper established a mechanism by which AKG extends lifespan in C. elegans via ATP-synthase and TOR inhibition ⁹. A 2020 Nature Communications paper described effects on age-related osteoporosis in mice via histone-methylation regulation ¹⁰.

Animal evidence — strongest for AKG. Asadi Shahmirzadi et al. 2020 in Cell Metabolism — AKG, administered late in life, extended median lifespan and compressed morbidity in aging mice ¹¹. The morbidity-compression result (treated mice spent more of their remaining life healthy) is notable.

Human evidence. A 2022 review in Trends in Endocrinology and Metabolism summarized human dietary AKG supplementation ¹². The human-RCT base is much earlier-stage than urolithin A's.

Canine evidence. Effectively absent in the public literature. Body-weight-scaled translation from rodent food-supplementation studies.

Dose. Human supplementation typically 1–3 g/day. Vector Canis doses Ca-AKG body-weight-scaled for adult-to-senior medium-large breeds.

Head to head

Axis	Urolithin A	Ca-AKG
Primary mechanism	Mitophagy (damaged-mitochondria clearance)	Krebs-cycle metabolism + histone-methylation regulation + ATP-synthase / TOR signaling
Strongest evidence type	Human RCTs (muscle, mitochondrial biomarkers)	Mouse lifespan + morbidity compression
Canine RCT base	None at Vector Canis doses	None
Body of human RCT data	Substantial — multiple independent groups	Earlier-stage; review summarizes 12
Cellular target	Mitochondria (selective quality control)	Mitochondria + nuclear epigenetic regulation

They target different mechanisms and combine well. Mitophagy (urolithin A) clears the damaged mitochondria; Krebs-cycle metabolism (Ca-AKG) supports the surviving ones. Saying "one is better than the other" is the wrong question. The right question is "which mechanism do I want to support, and what is the evidence base?"

Why we stack both in Vector Canis

A few reasons:

1. Mechanistic complementarity. Mitophagy and Krebs-cycle support are independent axes. Combining them covers more of the mitochondrial-quality-control story than either alone.
2. Evidence-base complementarity. Urolithin A has stronger human-RCT evidence; Ca-AKG has stronger mouse-lifespan evidence. Combining them gives breadth across evidence types.
3. Dose mathematics. Daily supplementation of each at body-weight-scaled doses appropriate for daily use is more sensible than maximum-dose monotherapy.
4. Practical packaging. Two separate bottles is harder to comply with than one daily formula.

We also include spermidine (autophagy induction — a third independent cellular-quality-control mechanism) and resveratrol (a complementary polyphenol). The pillar guide — Longevity for Dogs — covers each in detail.

What this comparison does not settle

• It does not give you direct canine-RCT data. Neither urolithin A nor Ca-AKG has been studied in dogs in published RCTs at supplementation doses; we extrapolate from the cross-species mechanism work and the human / rodent evidence base.
• It does not promise lifespan extension in dogs. The mouse AKG lifespan data is striking ¹¹, but canine-specific lifespan-extension data does not exist for any supplement.
• It does not address dose optimization. The doses in Vector Canis are body-weight-scaled from the human and rodent research; whether they are optimal for canine physiology is an open empirical question.
• It does not address breed differences. Small breeds, medium-large breeds, and giant breeds have meaningfully different aging trajectories; the right dose-per-kg and the right starting age may differ across breed size categories.

Bottom line

Urolithin A: mitophagy axis, strong human-RCT evidence (especially for muscle and mitochondrial biomarkers), no direct canine RCT data. Ca-AKG: Krebs-cycle axis, strong mouse-lifespan-and-morbidity-compression evidence, no direct canine RCT data. Best together: combined in Vector Canis at body-weight-scaled doses for adult-to-senior medium-large breeds, with veterinary-formulation safety review.